Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:09 2024-05-31 am EDT			5-day change	1st Jan Change
25.74 ^EUR	+1.82%		+1.90%	-30.41%

May. 31	Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	MT
May. 31	Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	MT

Galapagos : Galapagos creates new subscription right plans

May 17, 2024 at 03:05 am EDT

Galapagos NV

Galapagos NV

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date16 may 2024 - 22:09

Statutory nameGalapagos NV

TitleGalapagos creates new subscription right plans

Previous result

Next result

Related downloads

202405160000000026_press-release-subscription-right-plans-2024-eng.pdf(opens in a new window)

202405160000000026_press-release-subscription-right-plans-2024-nl.pdf(opens in a new window)

Date last update: 17 May 2024

Attachments

Original Link
Permalink

Disclaimer

Galapagos NV published this content on 16 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 May 2024 07:04:04 UTC.

Latest news about Galapagos NV

Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	May. 31	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	May. 31	MT
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture	May. 16	MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S	May. 15	CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024	May. 03
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	Apr. 08	CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	Mar. 28	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	Mar. 28	MT
Galapagos NV Announces Board Changes	Mar. 27	CI
Galapagos to Seek Acquisitions	Feb. 23	CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024	Feb. 23
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors	Feb. 21	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	Feb. 15	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	Feb. 01	MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding	Jan. 30	CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	Jan. 30	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	Jan. 05	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	Jan. 05	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	Jan. 04	MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug	Jan. 04	DJ
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets	Jan. 04	MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets	Jan. 03	MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV	Jan. 03	CI

Chart Galapagos NV

Duration

Period

More charts

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.74 EUR

Average target price

36.73 EUR

Spread / Average Target

+42.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GALAPAGOS NV	-30.41%	1.84B
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research